Syndrome News and Research

RSS

A 'short list' of signature peptides for tracking down SARS-CoV-2 virus

SPI researchers (Marcoule) used proteomics to identify signature peptides of the SARS-CoV-2 virus expressed in vitro.

10 Aug 2020

Mass spectrometry shows potential for rapid SARS-CoV-2 detection

A team from SPI in Marcoule detected by mass spectrometry, in 3 minutes and without specific reagents, signature peptides of the SARS-CoV-2 virus in clinical samples. It thus provides a proof of concept of the use of this method as a possible alternative to PCR, currently the reference method.

10 Aug 2020

Reopening after COVID-19 lockdown and impact on disease

The study shows that 8 of 11 European countries had significantly more cases after reopening, but Germany, the UAE, and Poland had fewer. In five of the eight, the cases increased, peaked, and then dropped before the reopening happened, while Romania and Serbia showed a rapid rise before reopening.

10 Aug 2020

SARS-CoV-2 droplets travel further and last longer than thought, and even more in humid air

The ongoing COVID-19 pandemic is spread by respiratory aerosols, in which tiny droplets of saliva and mucus containing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are expelled from the upper respiratory tract. Though quite a few studies have investigated the viral load of such droplets, not much is known about how far these droplets move or how long they linger in the air, even though such information is crucial to determining how infectious they are.

10 Aug 2020

Planning low-risk school re-opening in the U.S.

With the rapid and extensive spread of the COVID-19 pandemic, the USA witnessed an almost universal closure of schools in March 2020. Now, after months of enforced online schooling, federal authorities are impatient for schools to re-open. However, how should this be done without endangering the lives of teachers, administrative and other non-teaching staff, and students at school, and parents/other family members at home?

10 Aug 2020

People may have a pre-existing immune response to COVID-19 thanks to common colds

Now, a new study shows that some people have immune responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, thanks to how the body reacted the last time it caught a cold. This means that even if a person has not been exposed to the novel coronavirus, the body has a memory of it and can trigger an immune response to fight the infection.

10 Aug 2020

Vaccine 'nationalism' will slow coronavirus fight if poor countries are left exposed

As the coronavirus vaccine race charges on, many of the investigational candidate vaccines are nearing the final stages of human trials. The results of these trials will determine if they will be granted the green light to manufacture and distribute the vaccine to countries across the globe.

10 Aug 2020

Chronic fatigue syndrome and Gulf War illness produce different patterns of brain activity after moderate exercise

A brain imaging study of veterans with Gulf War illness (GWI) and patients with chronic fatigue syndrome (CFS) (sometimes called myalgic encephalomyelitis), has shown that the two illnesses produce distinctly different, abnormal patterns of brain activity after moderate exercise.

10 Aug 2020

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

A recent case study published in the Journal of Applied Laboratory Medicine in August 2020 illustrates this with its finding of persistent seronegativity in a patient confirmed to be SARS-CoV-2 positive.

10 Aug 2020

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.

10 Aug 2020

USA the source of most of New Zealand's coronavirus cases

New Zealand, an island country in the southwestern Pacific Ocean, is marked by its early and fierce determination to totally arrest the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the viral illness that is causing the current COVID-19 pandemic.

9 Aug 2020

How have non-pharmaceutical interventions helped in COVID-19?

The COVID-19 pandemic shows no signs of abating, with outbreaks in many spots still occurring across the world. From the start, health organizations and governments were focused on implementing non-pharmaceutical interventions (NPIs) in the absence of any effective antivirals or vaccines.

9 Aug 2020

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

A new study by researchers from the Scripps Research Institute and Novavax Inc. in the US affirms the structural integrity of the full-length SARS-CoV-2 spike glycoprotein immunogen. It enables the interpretation of immune responses to this multivalent nanoparticle immunogen. Their results are currently available on bioRxiv preprint server.

9 Aug 2020

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

NVX-CoV2373, a recombinant nanoparticle vaccine developed by Novavax and manufactured at Emergent Biosolutions, was found to be well tolerated and immunogenic – inducing T-cell response and neutralization antibodies four-fold higher than the mean observed in hospitalized coronavirus disease (COVID-19) patients, shows a recent study available on the medRxiv* preprint server.

9 Aug 2020

Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19)

Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.

9 Aug 2020

Community-based sampling needed for COVID-19 control, say researchers

Researchers in the UK have warned that it will be essential to carry out community-based sampling in addition to symptomatic testing if the ongoing transmission of severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) is going to be properly understood and controlled.

9 Aug 2020

FDA approves opioid agonist for management of moderate to severe acute pain in adults

Today, the U.S. Food and Drug Administration approved Olinvyk (oliceridine), an opioid agonist for the management of moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid and for whom alternative treatments are inadequate.

9 Aug 2020

Research identifies a potential therapeutic target for clogged arteries

New work led by Carnegie's Meredith Wilson and Steve Farber identifies a potential therapeutic target for clogged arteries and other health risks that stem from an excess of harmful fats in the bloodstream. Their findings are published by PLOS Genetics.

7 Aug 2020

Advanced analysis offers new insights into immune system’s role in severe COVID-19

By conducting advanced analyses of immune system activation in patients with severe COVID-19, researchers at Karolinska Institutet have managed to identify several cell types that play a key part in the immune response to the new coronavirus and the hyperinflammation seen in severe cases of the disease.

7 Aug 2020

Large-scale analysis of Alport syndrome reveals the effectiveness of existing treatments

A large-scale analysis of the clinical characteristics of Alport syndrome in Japanese patients has revealed that the effectiveness of existing treatment with ACE inhibitors and/or angiotensin receptor blockers (RAS inhibitors) varies depending on the type of mutation in the syndrome's causal gene (COL4A5).

7 Aug 2020

Syndrome News and Research

A 'short list' of signature peptides for tracking down SARS-CoV-2 virus

Mass spectrometry shows potential for rapid SARS-CoV-2 detection

Reopening after COVID-19 lockdown and impact on disease

SARS-CoV-2 droplets travel further and last longer than thought, and even more in humid air

Planning low-risk school re-opening in the U.S.

People may have a pre-existing immune response to COVID-19 thanks to common colds

Vaccine 'nationalism' will slow coronavirus fight if poor countries are left exposed

Chronic fatigue syndrome and Gulf War illness produce different patterns of brain activity after moderate exercise

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

USA the source of most of New Zealand's coronavirus cases

How have non-pharmaceutical interventions helped in COVID-19?

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19)

Community-based sampling needed for COVID-19 control, say researchers

FDA approves opioid agonist for management of moderate to severe acute pain in adults

Research identifies a potential therapeutic target for clogged arteries

Advanced analysis offers new insights into immune system’s role in severe COVID-19

Large-scale analysis of Alport syndrome reveals the effectiveness of existing treatments

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News